These pathways contribute to the response to Interferon-gamma, alpha interferon proteins, tumor necrosis factor, transplant rejection, inflammatory response, and KRAS17, indicating a higher level of tumor immune response in the ICD-high subgroup. This evidence concerns the gene IFNG and neoplasm.